Kersten 2013.

Study characteristics
Methods	Participants randomly assigned to intervention or control group via stratified randomisation process. Each nursing home represented 1 stratum. An independent research co‐ordinator randomly allocated participants (1:1) within each stratum. The size of the stratum varied from 2–15 participants, with a median of 4.
Participants	Sample size: 101 Setting: 22 nursing homes in Norway Time frame for trial recruitment: 11 months (2008–2009) Inclusion criteria Long‐term nursing home residents ADS score ≥ 3 Exclusion criteria Blindness Deafness Aphasia Delirium Severe dementia (score 3 on the Clinical Dementia Rating scale) Baseline characteristics Age: median 85–86 years Sex: 69/87 female Baseline ADS score: median 4 % without dementia: 40% in intervention group, 20% in control group % mild dementia: 36% in intervention group, 47.5% in control group % moderate dementia: 23% in intervention group, 32.5% in control group CCI: median 3 in both groups Baseline MMSE: median 20.5 in intervention group, median 20 in control group
Interventions	Intervention: pharmacist‐led anticholinergic reduction intervention (in collaboration with GPs). Multidisciplinary drug review conducted within 3 days of baseline assessment. Drug reviews were guided by the ADS score to advise nursing home physicians about whether to discontinue or replace an anticholinergic drug with an alternative. Anticholinergic drugs were discontinued or replaced with a drug alternative with less or no anticholinergic activity. When drug alternatives were unavailable, reduction in dosage was attempted to reduce the anticholinergic burden. Control: usual care. For ethical reasons, similar drug reviews were conducted for the control group after the last follow‐up.
Outcomes	Cognitive outcomes measured with CERAD 10‐wordlist Global MMSE Follow‐up: 4 and 8 weeks
Notes